BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...

Oncotelic Therapeutics Inc. (OTC:OTLC), the RNA-based therapeutics company, says it is making progress advancing its antisense oligonucleotide (ASO) platform, fueled by promising clinical data and ...

The ability to make synthetic DNA and RNA by chemical or enzymatic means has revolutionized genetic research and drug discovery. Antisense technology employs short, chemically synthesized ...

Drugmakers can now call on a host of RNA therapeutic modalities, but small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) drugs still garner the highest upfront payments. Oligo therapies ...

A new pediatric brain cancer treatment uses a short RNA strand to shut down a deadly mutation. Introducing into a cell an exact match for a mutant protein’s mRNA, called an antisense oligonucleotide ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of RNA-based drugs can significantly enhance their effectiveness. These ...

Flamingo Therapeutics BV and Ionis Pharmaceuticals Inc.’s FTX-001 (also known as FLM-7523) is a potential first-in-class antisense oligonucleotide (ASO) targeting the human metastasis-associated lung ...

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of ...

Look inside a brain cell with Huntington’s disease or ALS and you are likely to find RNA clumped together. These solid-like clusters, thought to be irreversible, can act as sponges that soak up ...

ANN ARBOR, Mich. — In a remarkable display of bench to bedside science, a therapeutic developed by U-M’s Michelle Hastings, Ph.D. is now being used to treat twin girls with a rare form of juvenile ...